Daniel Kotlarz is a clinician-scientist focusing on translational research directed towards the ultimate goal of improving diagnosis and therapies for children with life-threatening very early onset inflammatory bowel diseases (VEO-IBD). In collaboration with Prof. Christoph Klein (Head of the Dr. von Hauner Children’s Hospital, LMU Munich) he is coordinating the translational research activities of the international VEO‑IBD Consortium at the site of the LMU Munich. With the support of a large global collaboration network, he has made major contributions to the field of intestinal inflammation by characterizing patients with CASP8, IL10R, IL21R, LY96, RIPK1, and TGFB1 deficiencies. His studies have been published in the renowned journals Gastroenterology, The Journal of Allergy and Clinical Immunology, Nature Genetics, PNAS, The Journal of Experimental Medicine, and The New England Journal of Medicine. Furthermore, his translational genomic research has been recognized by several awards, including the Innovation Prize 2015 (German University Hospital Association), John Harries Prize 2019 (European Society of Paediatric Gastroenterology, Hepatology and Nutrition), Heinz Maier-Leibnitz-Prize 2020 (DFG and BMBF), and the ECCO Pioneer Award 2023 (European Crohn’s and Colitis Organisation).